Recurrent allograft disease: Viral hepatitis

Acta Gastro-Enterologica Belgica

Volumn 68, Issue 3, 2005, Pages 337-346

  Berenguer, Marina ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Adefovir; Cirrhosis; Donor; Fibrosis; Hepatitis B; Hepatitis C; Interferon; Lamivudine; Live donor liver transplantation; Liver transplantation; Ribavirin

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTIVIRUS AGENT; CALCINEURIN INHIBITOR; CORTICOSTEROID; HEPATITIS B ANTIBODY; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSIDE ANALOG; OKT 3; PEGINTERFERON; RIBAVIRIN;

ALLOGRAFT; ANEMIA; BONE MARROW SUPPRESSION; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DEATH; DISEASE COURSE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; DRUG POTENTIATION; GRAFT INFECTION; GRAFT SURVIVAL; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; NEPHROTOXICITY; NEUTROPENIA; PASSIVE IMMUNIZATION; RECURRENT DISEASE; REINFECTION; SIDE EFFECT; THROMBOCYTOPENIA; VIRUS HEPATITIS;

HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER TRANSPLANTATION; RECURRENCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 26944478203     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (117)

1. STEINMULLER T., SEEHOFER D., RAYES N. et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology, 2002, 35: 1528-35.
2. ROCHE B., FERAY C., GIGOU M. et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBs passive immunoprophylaxis. Hepatology, 2003, 38: 86-95.
3. BERENGUER M., LOPEZ-LABRADOR F.X., WRIGHT T.L. Hepatitis C and Liver transplantation. J. Hepatol., 2001, 35: 666-678.
4. BERENGUER M., PRIETO M., SAN JUAN F. et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology, 2002, 36: 202-210.
5. FORMAN L.M., LEWIS J.D., BERLIN J.A. et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology, 2002, 122: 889-896.
6. VILLAMIL F.G. Prophylaxis with anti-HBs immune globulins and nucleoside analogues after liver transplantation for HBV infection. J. Hepatol., 2003, 39: 466-474.
7. ROCHE B., SAMUEL D. Liver transplantation for hepatitis B virus-related liver disease: indications, prevention or recurrence and results. J. Hepatol, 2003, 39: S181-S189.
8. BERENGUER M., WRIGHT T.L. Treatment strategies for Hepatitis C: Intervention prior to liver transplant, pre-emptively or after established disease. Clinics in Liver Disease, 2003, 7 (3): 631-50, vii.
9. SAMUEL D., MULLER R., ALEXANDER G. et al. Liver transplantation in European patients with the hepatitis B surface antigen. N. Engl. J. Med., 1993, 329: 1842-1847.
10. DAVIES S.E., PORTMANN B.C., O'GRADY J.G. et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology, 1991, 13: 150-157.
11. MC MILLAN J., BOWDEN D., ANGUS P. et al. Mutations in the hepatitis B virus precore/core gene and core promoter in patients with severe recurrent disease following liver transplantation. Hepatology, 1996, 24: 1371-8.
12. ANGUS P.W., LOCARNINI S.A., MCCAUGHAN G.W. et al. Hepatitis B pre-core mutant infection is associated with severe recurrent disease after liver transplantation. Hepatology, 1995, 21: 14-8.
13. MC GORY R., ISHITANI M., OLIVEIRA W. et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation, 1996, 61: 1358-1364.
14. TERRAULT N., ZHOU S., COMBS C. et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology, 1996, 24: 1327-1333.
15. TERRAULT N.A., ZHOU S., MC CORY R.W. et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology, 1998, 28: 555-61.
16. CARMAN W., TRAUTWEIN C., VAN DEURSEN F. et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology, 1996, 24: 489-493.
17. GHANY M.G., AYOLA B., VILLAMIL F.G. et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology, 1998, 27: 213-22.
18. PROTZER-KNOLLE U., NAUMANN U., BARTENSCHLAGER R. et al. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation. Hepatology, 1998, 27: 254-63.
19. FONTANA R.J. Management of patients with decompensated HBV cirrhosis. Seminars in Liver Dis, 2003, 23 (1): 89-100.
20. MARZANO A, SALIZZONI M., DEBERNARDI-VENON W. et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J. Hepatol., 2001, 34: 903-910.
21. YU A.S., KEEFFE E.B. Nucleosides analogues and other antivirals for treatment of hepatitis B in the peritransplant period. Clin. Liver Dis., 2003, 7: 551-72.
22. MARKOWITZ J.S., MARTIN P., CONRAD A.J. et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology, 1998, 28: 585-9.
23. YAO F.Y., OSORIO R.W., ROBERTS J.P. et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl. Surg., 1999, 5: 491-496.
24. YOSHIDA E.M., ERB S.R., PARTOVI N. et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl. Surg., 1999, 5(6): 520-525.
25. ANGUS P.W., MCCAUGHAN G.W., GANE E.J. et al. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl., 2000, 6: 429-433.
26. HAN S.H., OFMAN J., HOLT C. et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl., 2001, 6: 741-8.
27. MC CAUGHAN G.W., SPENCER J., KOOREY D. et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus pre-core mutant-associated infection : high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low-dose hepatitis B immune globulin. Liver Transpl. Surg., 1999, 6: 512-9.
28. DODSON S.F., DE DODSON S.F., DE VERA M.E. et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl., 2000, 6: 434-439.
29. BUTI M., PRIETO M., CASAFONT F. et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J. Hepatol., 2003, 38: 811-7.
30. SANCHEZ-FUEYO A., RIMOLA A., GRANDE L. et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology, 2000, 31: 496-501.
31. SANCHEZ-FUEYO A., MARTINEZ-BAUER E., RIMOLA A. Hepatitis B vaccination after liver transplantation. Hepatology, 2002, 36: 257.
32. ANGELICO M., DI PAOLO D., O TRINITO M. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology, 2002, 35: 176-181.
33. BIENZLE U., GUNTHER M., NEUHAUS R., NEUHAUS P. Successful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: preliminary results. Liver Transpl., 2002, 8: 562-4.
34. BAIN V.G., KNETEMAN N.M., MA M.M. et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation, 1996, 62: 1456-1459.
35. VILLENEUVE J., CONDREAY L.D., WILLEMS B. et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology, 2000, 31: 207-210.
36. YAO F.Y., BASS N.M. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J. Hepatol., 2000, 33: 301-7.
37. KAPOOR D., GUTPAN R.C., WAKIL S. et al. Beneficial effects of lamivudine in hepatitis B virus related decompensated cirrhosis. J. Hepatol., 2000, 33: 308-12.
38. YAO F.Y., TERRAULT N.A., FREISE C. et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology, 2001, 34: 411-416.
39. PERRILLO R.P., WRIGHT T., RAKELA J. et al. A muticenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology, 2001, 33: 424-432.
40. FONTANA R.J., KEEFFE E.B., CAREY W. et al. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl., 2002, 8: 433-439.
41. ANDREONE P., BISELLI M., GRAMENEZI A. et al. Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver transplantation. Transplantation, 2002, 74: 1119-1124.
42. FONTANA R.J., HANN H.-W.L., PERRILLO R.P. et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology, 2002, 123: 719-727.
43. MELEGARI M., SCAGLIONI P.P., WANDS J.R. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology, 1998, 27: 628-33.
44. SEEHOFER D., RAYES N., STEINMÜLLER T. et al. Occurrence and clinical outcome of lamivudine resistant hepatitis B after liver transplantation. Liver Transpl., 2001, 7: 976-982.
45. BOCK C.T., TILLMANN H.L., TORRESI J. et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology, 2002, 122: 264-273.
46. SAAB S., KIM M., WRIGHT T.L. et al. Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. Gastroenterology, 2000, 119: 1382-1384.
47. ROSENAU J., BAHR M.J., TILLMAN H.L. et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation: possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J. Hepatol., 2001, 34: 895-902.
48. SEEHOFER D., RAYES N., NAUMANN U. et al. Preoperative antiviral treatment and postoperative prophylaxis in HBV DNA positive patients undergoing liver transplantation. Transplantation, 2001, 72: 1381-1385.
49. SCHIFF E.R., LAI C.L., HADZIYANNIS S. et al. Adefovir Dipivoxil therapy for lamivudine-resistant hepatitis in pre- and post-liver transplantation patients. Hepatology, 2003, 38: 1419-1427.
50. MUTIMER D., DUSHEIKO G., BARRETT C. et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation, 2000, 70: 809-815.
51. MUTIMER D., PILLAY D., DRAGON E. et al. High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J. Hepatol., 1999, 30: 715-721.
52. NAOUMOV N.V., LOPES A.R., BURRA P. et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. J. Hepatol., 2001, 34: 888-894.
53. BERENGUER M., WRIGHT T.L. Treatment of recurrence of hepatitis B in transplant patients. J. Hepatol., 2003, 39: S190-S193.
54. PERRILLO R., RAKELA J., DIENSTAG J. et al. Multicenter Study of Lamivudine therapy for hepatitis B after Liver Transplantation. Hepatology, 1999, 29: 1581-1586.
55. PRIETO M., GOMEZ M.D., BERENGUER M. et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl., 2001, 7: 51-58.
56. MUÑOZ S.J. Use of hepatitis B core antibody-positive donors for liver transplantation. Liver Transpl., 2002, 8: S82-S87.
57. ROCHE B., SAMUEL D., FERAY C. et al. Retransplantation of the liver for recurrent hepatitis B virus infection: the Paul Brousse experience. Liver Transpl. Surg., 1999, 5: 166-174.
58. INTERNATIONAL LIVER TRANSPLANTATION SOCIETY HCV CONSENSUS GROUP. Report of the First International Liver Transplant Society Consensus Conference on Liver Transpl.antation and Hepatitis C. Liver Transpl., 2003, 9(11): suppl 3.
59. GARCIA-RETORTILLO M., FORNS X., FELIU A. et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology, 2002, 35: 680-7.
60. BERENGUER M. Natural history of recurrent hepatitis C. Liver Transpl., 2002, 8 (Suppl 1):S14-S18.
61. McCaughan G.W., Zekry A. Pathogenesis of hepatitis C virus recurrence in the liver allograft. Liver Transpl., 2002, 8 (Suppl. 1): S7-S13.
62. BERENGUER M., FERRELL L., WATSON J. et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J. Hepatol., 2000, 32: 673-684.
63. GANE E., PORTMANN B., NAOUMOV N. et al. Long-Term outcome of hepatitis C infection after liver transplantation. N. Engl. J. Med., 1996, 334: 815-820.
64. PRIETO M., BERENGUER M., RAYÓN M. et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology, 1999, 29: 250-256.
65. TESTA G., CRIPPIN J.S., NETTO G.J. et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl., 2000, 6: 553-561.
66. SANCHEZ-FUEYOS A., RESTREPO J.-C., QUINTÓ LLORENC. et al. Impact of the recurrence of hepatitis C infection after liver transplantation on the long term viability of the graft. Transplantation, 2002, 73: 56-63.
67. BERENGUER M., CRIPPIN J., GISH R. et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology, 2003, 38: 34-41.
68. BERENGUER M., RAYÓN M., PRIETO M. et al. Are post-transplantation protocol liver biopsies useful in the long-term? Liver transplantation, 2001, 7: 790-6.
69. SEBAGH M., RIFAI K., FERAY C. et al. All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology, 2003, 37: 1293-301.
70. BERENGUER M., AGUILERA V., PRIETO M. et al. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern? Liver Transpl., 2003, 1152-1158.
71. SCHLUGER L., SHEINER P., THUNG S. et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology, 1996, 23: 971-976.
72. DOUGHTY A.L., SPENCER J.D., COSSART Y.E., MC CAUGHAN G.W. Cholestatic hepatitis post liver transplant is associated with persistently high serum hepatitis C virus RNA levels. Liver Transpl. Surg., 1998, 4: 15-21.
73. BERENGUER M., PRIETO M., RAYÓN J.M. et al. Natural history of clinically compensated HCV-related graft cirrhosis following liver transplantation. Hepatology, 2000, 32: 852-8.
74. BURAK K.W., KREMERS W.K., BATTS K.P. et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl., 2002, 8: 362-369.
75. BERENGUER M. Outcome of post-transplantation HCV-disease- is it the host, the virus or how we modify the host and/or the virus? Liver Transpl., 2002, 8: 889-891.
76. EASON J.D., NAIR S., COHEN A.J., BLAZEK J.L., LOSS G.E. Jr. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation, 2003, 75: 1396-9.
77. BRILLANTI S., VIVARELLI M., DE RUVO N. et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl., 2002, 8: 884-888.
78. SHEINER P.A., SCHWARTZ M.E., MOR E. et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology, 1995, 21: 30-34.
79. BERENGUER M., PRIETO M., CORDOBA J. et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J. Hepatol., 1998, 28: 756-763.
80. ROSEN H.R., SHACKLETON C.R., HIGA L. et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am. J. Gastroenterol., 1997, 92: 1453-7.
81. ZEKRY A., GLEESON M., GUNEY S., MC CAUGHAN G.W. A prospective cross-over study comparing the effect of mycophenolate vs azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl., 2004, 10: 52-57.
82. JAIN A., KASHYAP R., DEMETRIS A.J. et al. A prospective randomized trial of Mycophenolate Mofetil in liver transplant recipients with hepatitis C. Liver Transpl., 2002, 8: 40-46.
83. FASOLA C.G., NETTO G.J., JENNINGS L.W. et al. Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil. Transplant. Proc., 2002, 34: 1563-4.
84. CHARLTON M., SEABERG E., WIESNER R. et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology, 1998, 28: 823-30.
85. SREEKUMAR R., GONZALEZ-KOCH A., MAOR-KENDLER Y. et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology, 2000, 32: 1125-30.
86. FERAY C., CACCAMO L., ALEXANDER G.J.M. et al. European Collaborative Study on factors influencing the outcome after liver transplantation for hepatitis C. Gastroenterology, 1999, 117: 619-25.
87. LOPEZ-LABRADOR F.X., BERENGUER M., SEMPERE A. et al. Genetic variability of hepatitis C virus NS3 protein in human leukocyte antigen-A2 liver transplant recipients with recurrent hepatitis C. Liver Transpl., 2004, 10: 217-227.
88. WALI M., HARRISON R.F., GOW P.J., MUTIMER D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut, 2002, 51: 248-252.
89. EVERSON G.T. Role of adult living donation in patients with hepatitis C: Con. Liver Trans., 2003, 9: S64-S68.
90. RUSSO M., GALANKO J., BEAVERS K. et al. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl., 2004, 10: 340-346.
91. FERAY C., GIGOU M., SAMUEL D. et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann. Intern. Med., 1998, 128: 810-6.
92. WILLEMS B., EDE M., MAROTTA P. et al. Anti-HCV human immunoglobulin for the prevention of graft infection in HCV-related liver transplantation-A pilot study. J. Hepatol., 2002, 36: 32 (abstr.).
93. CRIPPIN J.S., SHEINER P., TERRAULT N.A. et al. A pilot study of the tolerability and efficacy of antiviral therapy in patients awaiting liver transplantation for hepatitis C. Liver Transpl.antation, 2002, 8: 350-355.
94. EVERSON G.T., TROUILLOT T., TROTTER J. et al. Treatment of decompensated cirrhotics with a slow-accelearting dose regimen (LADR) of interferon-alfa-2b plus ribavirin: safety and efficacy. Hepatology, 2000, 32: 308A.
95. FORNS X., GARCIA-RETORTILLO M., SERRANO T. et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J. Hepatol., 2003, 39: 389-396.
96. MAZZAFERRO V., TAGGER A., SCHIAVO M. et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transpl. Proc., 2001, 33: 1355-1357.
97. TERRAULT N., KHALILI M., STRALEY S. et al. Efficacy and tolerability of preemptive interferon (IFN) vs IFN plus ribavirin (RBV) treatment in hepatitis C virus (HCV) infected liver transplant recipients. Hepatology, 2003, 38 (Suppl. 1): 158A (abst).
98. BIZOLLON T., PALAZZO U., DUCERF C. et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology, 1997, 26: 500-504.
99. ALBERTI A.B., BELLI L.S., AIROLDI A. et al. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study. Liver Transpl., 2001, 7: 870-6.
100. GOPAL D.V., RABKIN J.M., BERK B.S. et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl., 2001, 7: 181-90.
101. AHMAD J., DODSON S.F., DEMETRIS A.J., FUNG J.J., SHAKIL A.O. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl., 2001, 7: 863-9.
102. DE VERA M.E., SMALLWOOD G.A., ROSADO K. et al. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis Cafter liver transplantation. Transplantation, 2001, 71: 678-86.
103. NARAYANAN M., POTERUCHA J.J., EL-AMIN O.M. et al. Treatment of posttransplantation recurrence of hepatitis C wih interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl., 2002, 8: 623-9.
104. LAVEZZO B., FRANCHELLO A., SMEDILE A. et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus twelve month course of interferon alfa 2b with ribavirin. J. Hepatol., 2002, 37: 247-52.
105. SAMUEL D., BIZOLLON T., FERAY C. et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology, 2003, 124: 642-50.
106. FIRPI R.J., ABDELMALEK M.F., SOLDEVILA-PICO C. et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl., 2002, 8: 1000-6.
107. ABDELMALEK M.F., FIRPI R.J., SOLDEVILA-PICO C. et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl., 2004, 10:, 199-207.
108. BIZOLLON T., ADMED S.N.S., RADENNE S. et al. Long term histologic improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplant patients with hepatitis C recurrence. Gut, 2003, 52: 283-7.
109. SAAB S., LY D., HAN S.B. et al. Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients? Liver Transpl., 2002, 8: 449-57.
110. BIGGINS S.W., BELDECOS A., RABKIN J.M., ROSEN H.R. Retransplantation for hepatic allograft failure: prognostic modeling and ethical considerations. Liver Transpl., 2002, 8: 313-322.
111. ROSEN H., O'REILLY P., SHACKLETON C. et al. Graft loss following liver transplantation in patients with chronic hepatitis C. Transplantation, 1997, 62: 1773-1776.
112. SHEINER P.A., SCHLUGER L.K., EMRE S. et al. Retransplantation for recurrent hepatitis C. Liver Transpl. Surg., 1997, 3: 130-6.
113. FACCIUTO M., HEIDT D., GUARRERA J. et al. Retransplantation for late liver graft failure: predictors of mortality. Liver Transpl., 2000, 6: 174-179.
114. ROSEN H.R., MADDEN J.P., MARTIN P. A model to predict survival following liver retransplantation. Hepatology, 1999, 29: 365-70.
115. ROAYAIE S., SCHIANO T.D., THUNG S.N. et al. Results of retransplantation for recurrent hepatitis C. Hepatology, 2003, 38: 1428-36.
116. GHOBRIAL R.M. Retransplantation for recurrent hepatitis C in the Model for End-stage liver disease era: how should we or shouldn't we? Liver Transpl., 2003, 9: 1025-1027.
117. BERENGUER M., PRIETO M., PALAU A. et al. Severe recurrent hepatitis C following liver retransplantation for HCV-related graft failure. Liver Transpl., 2003, 9: 228-35.